Close

Anti-PSA (5A10)-CD147 CAR-MA (CARMA-W2233)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-PSA chimeric antigen receptor (CAR) is constructed for the engineering of macrophage cells to target human PSA and induce target cell phagocytosis. The macrophage cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PSA antibody (5A10) linked to CD147 signaling domains. The vector product was designed for the treatment of Prostate cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PSA
  • Cell Type
  • Macrophage
  • Targeting Diseases
  • Prostate cancer
  • Vector Name
  • pCDCAR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Size
  • 10 µg
  • Storage
  • Store at -20°C for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • 5A10
  • Hinge
  • IgG1
  • TM
  • CD147
  • ICD
  • CD147
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(IgG1)-TM(CD147)-ICD(CD147)
  • Discription of Signaling Cassetes
  • To breakdown the "physical barrier" of the tumour matrix, CD147 is used as the signaling domain. It's a membrane molecule that is essential for ECM remodelling via the expression of MMPs.

Target

  • Target
  • PSA
  • Target Species
  • Human
  • Clone
  • 5A10
  • Host
  • Mouse
  • Gene Name
  • Kallikrein related peptidase 3
  • Introduction
  • Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. The gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. It encodes a single-chain glycoprotein, a protease which is synthesized in the epithelial cells of the prostate gland, and is present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. The serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
  • Alternative Names
  • KLK3; kallikrein related peptidase 3; APS; PSA; hK3; KLK2A1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-PSA (5A10) ICD(CD147) CAR-MA Plasmid, pCDCAR1 (CARMA-W2233). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.